Symbol

Quantity

Purchase Price Per Share

Total Cost 

Current Quote

Barchart Link

Stock Weekly 

News

1

AIMT

1. The stock has been in existence since 2016.
2. The Stock picked at 39 and the lowest was 10.
3. The technical opinion is moderate to strong sale.
4. AIMT has just hit the all-time 52 week low today. They’ve recently published good news on their AR101 clinical results and with no life-threatening adverse results. There is a high percentage of probability the BLA will be granted Fast track designation by the FDA, based on recent data results.

5. Aimmune Therapeutics (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, cautions stakeholders against drawing conclusions from the Institute for Clinical…

    AIMT : 19.45 (+1.04%)
6. Opinion: The company in the long term might have success if their products attract more sources. In the short term, for now, indications are the sale of the stock.
7. The current consensus among 10 polled investment analysts is to buystock in Aimmune Therapeutics Inc. This rating has held steady since July, when it was unchanged from a buyrating.

8. Stock Price Forecast

   The 10 analysts offering 12-month price forecasts for Aimmune Therapeutics Inc have a median target of 45.00, with a high estimate of 79.00 and a low estimate of 24.00. The median estimate represents a +131.36% increase from the last price of 19.45.

   

   https://money.cnn.com/quote/forecast/forecast.html?symb=AIMT

2

AKAOQ

1.  The stock has been in existence since 2015.
2. The Stock Picked at 27  and now is at its lowest 0.011.
3. The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

4. The 1 analysts offering 12-month price forecasts for Achaogen Inc have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 2.00. The median estimate represents a +17,291.30% increase from the last price of 0.01.

   
5. Some forecasts also recommend holding.
6. Note stock is at is the lowest point right now.

7. Achaogen, Inc. Announces Results of Auction for Substantially All Company Assets.

8. Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%

9. It seems this company is in serious danger. 

3

AKER

1. This company has been in existence since 2009.
2. High peek was 575 in 2009 and currently 0.43.
3. The technical recommendation is moderate sell, 

4. The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction. Longer-term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

   5.CNN: 

   The 1 analysts offering 12-month price forecasts for Akers Biosciences Inc have a median target of 32.00, with a high estimate of 32.00 and a low estimate of 32.00. The median estimate represents a +7,256.32%increase from the last price of 0.44.

   

   https://money.cnn.com/quote/forecast/forecast.html?symb=aker

   6.The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Akers Biosciences, Inc. Common Stock — AKERGlobeNewswire – Mon Jul 29, 7:01AM CDT

   7. Current indicators report the moderate sale.

   8. Opinions:

   On June 21, 2019, Akers Biosciences, Inc. (the “Company”) received a complaint, filed by Novotek Therapeutics Inc., and Novotek 

   This company is finished. No products in pipeline. 

   They are going down, period. Saw Fuel Cell go across ticker little while ago. Owned 3-4 yrs ago at $3, crossed ticker at .19, hard to believe, aker will go to OTC. Should have never done RS, shows management are SOOOOO UnexperienceD in business. I would have been delisted and went from there.

4

ALT

1. This Company has been around since 2015.
2. The high pick was over 1000 in Jan 2017, then it took a nosedive.
3. It has been following a low trend in the past year no noticeable gains.
4. The current indicators are strong sell and also had an indicator of strong buy-in barchart.

5. The 1 analysts offering 12-month price forecasts for Altimmune Inc have a median target of 8.30, with a high estimate of 8.30 and a low estimate of 8.30. The median estimate represents a +248.74% increase from the last price of 2.38.

   

6. The current consensus among 1 polled investment analysts is to buy stock in Altimmune Inc. This rating has held steady since July, when it was unchanged from a buy rating.Move your mouse over past
   months for detail

   

    

   7. News:

   Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.

   Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs

5

AMPE

1. This company has been around since 2009.
2. Highest Pick was around 7 and the lowest was 0.36.

3. The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction. Longer-term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

4. The 1 analysts offering 12-month price forecasts for Ampio Pharmaceuticals Inc have a median target of 14.00, with a high estimate of 14.00 and a low estimate of 14.00. The median estimate represents a +3,400.00%increase from the last price of 0.40.

    

   This stock seems in limbo.

5. Opinions:Ampio has gone through some tuff growing pains but all this conjecture is a waist of time. They are on the clock and some how they made it to this last phase and sadly it cost a lot of shareholder value. I see nothing but upside based on the history of the stock. We know that it will move North once the trial nears a conclusion and at .40 a no brainer. The thing I am watching is if the so called 
6. Overview of OA drugs in development from OARSI 2019 by a leading expert. The reporter didn’t get a few things correct (like FX006 is not “advancing”, it’s approved!) Conaghan was the lead study investigator in Zilretta’s last Phase 3. He does think anti-NGF drugs have potential, in spite of possible SAEs. SM04690 is also promising, particularly as a DMOAD. Ampion was not mentioned.
7. Michael Macaluso, Ampio CEO, noted, “As we are already dosing patients in our pivotal Phase III trial of Ampion, as a biological treatment for adults with pain due to severe osteoarthritis of the knee (OAK),
8. Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced the progress to date in the Company’s special protocol assessment (SPA) phase three clinical trial titled “A Randomized, Controlled, Double-Blind…
9. Ampio Updates Status of Pivotal Clinical Trial of Ampion to be Carried Out Under a SPAPR Newswire – Wed Feb 6, 7:30AM CST

   Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it had received an initial response from the U.S. Food and Drug Administration (FDA), Office of Tissue and Advanced Therapies division regarding…

    AMPE : 0.40 (+2.56%)

6

AVEO

1. Company has been around since 2011.
2. The highest pick was around 20 in 2011, the lowest at around 0.49 This year.
3. Indicators are sell and strong sell, some report moderate buy and hold.
4. CNN

   The 3 analysts offering 12-month price forecasts for Aveo Pharmaceuticals Inc have a median target of 2.00, with a high estimate of 3.00 and a low estimate of 1.00. The median estimate represents a +182.13% increase from the last price of 0.71.

   

The current consensus among 4 polled investment analysts is to buy stock in Aveo Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a buy rating.Move your mouse over past
months for detail

7

CBDG

1. Company has been around since 2016.
2. Stocks Low was around 0.13 and the high was around 3.50.

3. The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction. Longer-term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

4. THC Farmaceuticals Receives Patent Protection in the Republic of South Africa For Methods of Producing Antibody- Rich Cannabis and Honeysuckle Plants

5. THC Farmaceuticals Acquires Fifty Percent Interest In 78 Acres of California Land; Through Subsidiary CBDual Biotech Begins Retailing Charlotte’s Web CBD Rich Products; To Begin Clinical Trials

6.  

   1. 1. 

8

CBDS

1. Company has been around since 2011.
2. The high for this stock was 11 and the low was0.30.

3. The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction. Longer-term, the trend strength is Average. Long term indicators fully support a continuation of the trend.\

4. Other indicators recommend buy.

5. Cannabis Sativa Enters into Letter of Intent to Acquire Lacuna Botanicals CBD

   Like many marijuana stocks, this pot company loses money and is probably destined for the dustbin of Wall Street history, but it may be setting up for a low-risk, high-reward short term investment. Cannabis Sativa, Inc. (OTCMKTS: CBDS) is involved in many areas of the cannabis industry.

   

9

CCWOF

1. Company has been around since 2015.
2. At the low, the stock was 0.0049 at the high was 0.65
3. Technical recommendation is sell at this time.
4. Bar Chart

   The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

   Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

5. Global Energy Metals Receives TSX Venture Exchange Approval for Acquisition of Rights to Use Canada Cobalt’s Re-2OX Technology at Nevada Battery Metals ProjectCNW Group – Thu Jun 6, 2:22PM CDT

   Canada Cobalt Works Inc. (TSXV: CCW) (OTC: CCWOF) (Frankfurt: 4T9B) (the “Company” or “Canada Cobalt”) is pleased to announce that Global Energy Metals Corp. (“GEMC”) has received approval from the TSX…

    Canada Cobalt More Than Doubles Size of Castle Mine Land PackageCNW Group – Fri May 10, 1:30PM CDT

   Canada Cobalt Works Inc. (TSXV: CCW) (OTC: CCWOF) (Frankfurt: 4T9B) (the “Company” or “Canada Cobalt”) is pleased to announce that it has added approximately 4,800 hectares to its Castle mine land package,.

   

    

10

CERPQ

1. This stock has been active since 2015.
2. Higest price was 0.40 and lowest 0.001

3. The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

4. The 10 analysts offering 12-month price forecasts for Aimmune Therapeutics Inc have a median target of 45.00, with a high estimate of 79.00 and a low estimate of 24.00. The median estimate represents a +137.22% increase from the last price of 18.97.

    
5. No major new 

6. The 1 analysts offering 12-month price forecasts for Cereplast Inc have a median target of 37.50, with a high estimate of 37.50 and a low estimate of 37.50. The median estimate represents a +309,817.36% increase from the last price of 0.01.

   
7.  
   

11

CLWD

1. This stock has been around since 2003.
2. At its hight the price was 12 and at low 0.01

3. he Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

4. No Major News.
5. 
6. In the chat area, some believe the stock will move around election time.

12

CNAT

1. This stock has been around since 2014.
2. The sock high was around 11 and the low 0.23
3. Recommendations are a sale.
4. Barchart recommends a strong sale.

5. The 1 analysts offering 12-month price forecasts for Conatus Pharmaceuticals Inc have a median target of 1.50, with a high estimate of 1.50 and a low estimate of 1.50. The median estimate represents a +351.81% increase from the last price of 0.33.

   

   Analyst Recommendations

   The current consensus among 1 polled investment analysts is to hold stock in Conatus Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a hold rating.Move your mouse over past
   months for detail

   

   6.Will Conatus Pharmaceuticals (CNAT) Report Negative Q2 Earnings? What You Should Know

   7.Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More

   Conatus’ Emricasan Lags Primary Goal in Liver Function Study

   Conatus Down More Than 60% in the Past 90 Days: Here’s WhyZacks Equity Research – Zacks Investment Research – Tue May 28, 10:48AM CDT

   Conatus’ (CNAT) lead candidate, emricasan, developed for treating patients with fibrosis or cirrhosis caused by NASH misses the primary endpoint in two mid-stage studies that hits the stock massively.

   

13

DMPI

1. This stock has been around since 2014
2. Stock high was around 91 and the low 1.39
3. The stock tech recommendation is to sale
4. Barchart also recommends to sale however few recommend to buy and hold
5. DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)PR Newswire – Wed Jul 31, 7:00AM CDT
6. DelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma MultiformePR Newswire – Wed Jul 24, 7:30AM CDT
7. DelMar Presents Data Supporting VAL-083 as Potential Treatment for Pediatric Brain Tumors at SNO Pediatric Neuro-Oncology ConferencePR Newswire – Mon May 6, 4:30AM CDT

8. The 1 analysts offering 12-month price forecasts for DelMar Pharmaceuticals Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate represents a +143.90% increase from the last price of 1.64.

   

   Analyst Recommendations

   The current consensus among 1 polled investment analysts is to buy stock in DelMar Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a buy rating.Move your mouse over past
   months for detail